Resolvin E1 is a metabolite of eicosapentaenoic acid (EPA) which is one of the omega-3
polyunsaturated fatty acids (omega-3 PUFAs). The antiplatelet properties of omega-3 PUFAs …

Objective—To investigate the ability of resolvin E1 (RvE1) to regulate adenosine
diphosphate (ADP) activation of platelets via specific receptors because RvE1 reduces …

Abstract Resolvin E1 (RvE1) is an omega-3 eicosapentaenoic acid (EPA)–derived lipid
mediator generated during resolution of inflammation and in human vasculature via …

Background and aims Besides LDL-cholesterol, local vascular inflammation plays a key role
in atherogenesis. Efficient therapies to treat the inflammatory component of the disease have …

The family of resolvins consists of omega-3 fatty acid-derived mediators, including E series
resolvins generated from eicosapentaenoic acid (EPA), and carry potent anti-inflammatory …

Inflammation is a defensive response to injury and infection, but excessive or inappropriate
inflammation contributes to a range of acute and chronic human diseases. Clinical …

E-series resolvins are antiinflammatory and pro-resolving lipid mediators derived from the ω-
3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) that actively clear inflammation to …

Bioactive mediators derived from omega-3 eicosapentaenoic acid (EPA) elicit potent anti-
inflammatory actions. Here, we identified novel EPA metabolites, including 8, 18 …

Cardiovascular disease (CVD) represents a global burden with a prevalence that continues
increasing progressively. CVD comprises a group of disorders of the heart and blood …

Objective—Resolvin D1 (RvD1) limits neutrophil recruitment during acute inflammation and
is derived from omega-3 docosahexaenoic acid to promote catabasis. The contribution of its …